Overview of Multimodality Therapy

2016 ◽  
pp. 73-89
Author(s):  
Robert de Wilton Marsh ◽  
Marshall S. Baker
Keyword(s):  
Multimodality Therapy

scholarly journals Outcomes of Adult Ewing Sarcoma Treated with Multimodality Therapy: A Single-Institute Experience

2020 ◽  
Vol 09 (04) ◽  
pp. 191-194
Author(s):  
Ravi Chandran ◽  
Siva Prasad Kuruva ◽  
Rachana Chennamaneni ◽  
Stalin Bala ◽  
Meher Lakshmi Konatam ◽  
...  
Keyword(s):  
Metastatic Disease ◽  
Ewing Sarcoma ◽  
Univariate Analysis ◽  
Lactate Dehydrogenase Level ◽  
Serum Lactate ◽  
Normal Serum ◽  
Multimodality Therapy ◽  
Serum Lactate Dehydrogenase ◽  
Common Symptom ◽  
Localized Disease

Abstract Introduction Ewing sarcoma (ES) is more common in children and relatively rare in adults. Adult ES has poor prognosis than children. Treatment approaches for adults have been extrapolated from pediatric experience. Data on adult ES are very few because of its rarity in adults. The present study was done to analyze the clinical profile and outcome of adult ES. Aims The aim was to study the clinical and pathological treatment and outcomes in adult ES. Subjects and Methods Between 2010 and 2017, a total of 73 ES patients with age more than 18 years were retrospectively analyzed. Survival analysis was done by plotting Kaplan–Meier curves. Results A total of 73 patients were diagnosed with ES during 2010 to 2017. Among them, 43 (58.9%) had localized disease with a median age of 24.5 years. Males were 44 (60.3%) and females were 29 (39.7). Pain (75.3%) was the most common symptom at presentation. Nine patients had incomplete details and were excluded from the analysis. Among 21 (28.8%) patients, the lung (61.9%) was the most common site of metastasis followed by the bone, bone marrow, and brain. The median number of chemotherapy cycles in the localized disease was 14 (range 1–17), and in metastatic disease, it was 4 (range 1–7). Univariate analysis was done with respect to age (< 25 vs. ≥25), gender, elevated or normal serum lactate dehydrogenase level, tumor size (< 8 cm versus ≥8 cm), site (axial versus extremity), and neoadjuvant chemotherapy (NACT) given or not. NACT had a significant impact on overall survival (OS) and the rest had no effect. At a median follow-up of 40 months, the 3-year OS in localized disease was 87.4%. In metastatic disease, the median OS was 13 months with 3-year OS of 26%. Conclusions Outcomes with multimodality therapy in adult ES patients with localized disease are comparable to that of a pediatric cohort. However, metastatic disease has poor survival.

scholarly journals MA05.01 Second or Third Line Anti-PD-1 Therapy After Multimodality Therapy Including Total Pleurectomy in Malignant Pleural Mesothelioma

2019 ◽  
Vol 14 (10) ◽  
pp. S264-S265
Author(s):  
L. Lang-Lazdunski ◽  
Y.Z. Zhang ◽  
S. Popat ◽  
M. O'Brien ◽  
J. Steele ◽  
...  
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Multimodality Therapy ◽  
Pleural Mesothelioma ◽  
Third Line
Sign in / Sign up

Export Citation Format

Share Document